Royal Bank of Canada
NVCR icon

Royal Bank of Canada’s NovoCure NVCR Stock Holding History

Royal Bank of Canada’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$100K Sell
9,211
-3,619
-28% -$45.2K ﹤0.01% 5127
2025
Q4 		$166K Buy
12,830
+1,667
+15% +$21.4K ﹤0.01% 4894
2025
Q3 		$144K Buy
11,163
+471
+4% +$6.29K ﹤0.01% 5287
2025
Q2 		$191K Buy
10,692
+1,773
+20% +$30.9K ﹤0.01% 5203
2025
Q1 		$158K Buy
8,919
+689
+8% +$15.6K ﹤0.01% 4876
2024
Q4 		$245K Sell
8,230
-14,082
-63% -$298K ﹤0.01% 4650
2024
Q3 		$348K Buy
22,312
+2,191
+11% +$39.7K ﹤0.01% 4385
2024
Q2 		$345K Sell
20,121
-1,125
-5% -$19.8K ﹤0.01% 4307
2024
Q1 		$332K Sell
21,246
-41,826
-66% -$615K ﹤0.01% 4262
2023
Q4 		$941K Buy
63,072
+49,992
+382% +$669K ﹤0.01% 3713
2023
Q3 		$211K Buy
13,080
+1,059
+9% +$30.5K ﹤0.01% 4757
2023
Q2 		$499K Buy
12,021
+5,149
+75% +$320K ﹤0.01% 3953
2023
Q1 		$413K Sell
6,872
-12,474
-64% -$997K ﹤0.01% 4029
2022
Q4 		$1.42M Sell
19,346
-735
-4% -$55.3K ﹤0.01% 3211
2022
Q3 		$1.52M Buy
20,081
+1,473
+8% +$115K ﹤0.01% 3072
2022
Q2 		$1.29M Sell
18,608
-89
-0.5% -$6.7K ﹤0.01% 3268
2022
Q1 		$1.55M Sell
18,697
-2,121
-10% -$156K ﹤0.01% 3278
2021
Q4 		$1.56M Sell
20,818
-7,790
-27% -$782K ﹤0.01% 3379
2021
Q3 		$3.32M Buy
28,608
+4,674
+20% +$707K ﹤0.01% 2634
2021
Q2 		$5.31M Sell
23,934
-85,664
-78% -$16.7M ﹤0.01% 2277
2021
Q1 		$14.5M Sell
109,598
-74,975
-41% -$11.9M ﹤0.01% 1501
2020
Q4 		$31.9M Buy
184,573
+158,170
+599% +$21.6M 0.01% 941
2020
Q3 		$2.94M Buy
26,403
+5,660
+27% +$453K ﹤0.01% 2382
2020
Q2 		$1.23M Sell
20,743
-3,158
-13% -$208K ﹤0.01% 3003
2020
Q1 		$1.61M Sell
23,901
-90,659
-79% -$7.16M ﹤0.01% 2657
2019
Q4 		$9.65M Buy
114,560
+54,422
+90% +$4.39M ﹤0.01% 1659
2019
Q3 		$4.5M Buy
60,138
+45,843
+321% +$3.67M ﹤0.01% 2159
2019
Q2 		$904K Sell
14,295
-23,531
-62% -$1.19M ﹤0.01% 3390
2019
Q1 		$1.82M Buy
37,826
+9,333
+33% +$449K ﹤0.01% 2757
2018
Q4 		$953K Buy
28,493
+9,732
+52% +$356K ﹤0.01% 3205
2018
Q3 		$984K Sell
18,761
-119,381
-86% -$4.75M ﹤0.01% 3375
2018
Q2 		$4.32M Buy
138,142
+23,040
+20% +$641K ﹤0.01% 2124
2018
Q1 		$2.51M Buy
115,102
+7,067
+7% +$152K ﹤0.01% 2508
2017
Q4 		$2.18M Buy
108,035
+100,591
+1,351% +$1.94M ﹤0.01% 2657
2017
Q3 		$148K Buy
7,444
+7,112
+2,142% +$140K ﹤0.01% 4737
2017
Q2 		$6K Sell
332
-1,792
-84% -$23.1K ﹤0.01% 5985
2017
Q1 		$17K Sell
2,124
-1,311
-38% -$9.47K ﹤0.01% 5709
2016
Q4 		$27K Buy
+3,435
New +$27.6K ﹤0.01% 5603
2016
Q3 		– Sell
-2,180
Closed -$25K – 6520
2016
Q2 		$25K Sell
2,180
-17,220
-89% -$216K ﹤0.01% 5414
2016
Q1 		$281K Buy
+19,400
New +$278K ﹤0.01% 4113

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Royal Bank of Canada's NVCR Position: Q1 2026 in Review

Royal Bank of Canada reduced its NovoCure (NVCR) stake by 28% in Q1 2026, selling an estimated $45.2K and leaving 9,211 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #5127.

Royal Bank of Canada first reported a position in NVCR in Q1 2016 and has held it in 40 quarters since. The position peaked at $31.9M in Q4 2020. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Royal Bank of Canada held 9,211 shares of NovoCure worth $100K as of Q1 2026.
  • Royal Bank of Canada sold 3,619 NovoCure shares in Q1 2026, an estimated $45.2K.
  • NovoCure made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5127 holding.
  • Royal Bank of Canada first reported a position in NovoCure in Q1 2016 and has held it in 40 quarters since.
  • Royal Bank of Canada's NovoCure position peaked at $31.9M in Q4 2020.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.